Resource Summary Report

Generated by dkNET on Sep 1, 2026

HEY

RRID:CVCL_0297
Type: Cell Line

Proper Citation

RRID:CVCL_0297

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0297

Proper Citation: RRID:CVCL_0297

Description: Cell line HEY is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: PMID:3731068, PMID:4016745, PMID:12960427, PMID:19926575, PMID:20204287, PMID:22710073, PMID:23415752, PMID:24023729, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30485824, PMID:30894373, PMID:30971826, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEY

Synonyms: Hey

Cross References: BTO:BTO_0002590, EFO:EFO_0006580, MCCL:MCC:0000188, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:866, BioSample:SAMN03473280, cancercelllines:CVCL_0297, Cell_Model_Passport:SIDM00968, ChEMBL-Cells:CHEMBL3308082, ChEMBL-Targets:CHEMBL613869, CLS:305017, Cosmic:1102812, Cosmic:1524358, Cosmic-CLP:1479988, DepMap:ACH-002140, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:1479988, GEO:GSM659377, GEO:GSM1340581, GEO:GSM1669880, IARC_TP53:28489, PharmacoDB:HEY_541_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_0297, Wikidata:Q54883211

ID: CVCL_0297

Hierarchy: cvcl_4995

Record Creation Time: 20220427T220340+0000

Record Last Update: 20260829T233708+0000

Ratings and Alerts

No rating or validation information has been found for HEY.

No alerts have been found for HEY.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Li Y, et al. (2026) Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23374.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. Cell death & disease, 17(1), 202.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science advances, 12(16), eaeb0855.

Zhang F, et al. (2026) The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. Oncogenesis, 15(1).

Liu W, et al. (2025) Serum metabolic fingerprints encode functional biomarkers for ovarian cancer diagnosis: a large-scale cohort study. EBioMedicine, 115, 105706.

Ding C, et al. (2025) A Tumor-homing nanoplatform for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer. Cellular oncology (Dordrecht, Netherlands), 48(6), 1741.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(47), e11349.

Li DX, et al. (2025) COPB2 facilitates EDEM3-mediated mannose trimming to sustain ER homeostasis in ovarian cancer. Cellular oncology (Dordrecht, Netherlands).

Che X, et al. (2025) TRIM4 modulates the ubiquitin-mediated degradation of hnRNPDL and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer. Frontiers of medicine, 19(1), 121.

Wang W, et al. (2025) CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer. Translational oncology, 57, 102414.

Guo Z, et al. (2025) Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. EBioMedicine, 119, 105879.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. Molecular cancer therapeutics, 23(11), 1652.

Yang S, et al. (2023) Function of m5C RNA methyltransferase NOP2 in high-grade serous ovarian cancer. Cancer biology & therapy, 24(1), 2263921.

Wen J, et al. (2023) TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3. FEBS letters, 597(24), 3072.

Young KM, et al. (2023) Correlating mechanical and gene expression data on the single cell level to investigate metastatic phenotypes. iScience, 26(4), 106393.

Yang J, et al. (2022) Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. Translational oncology, 16, 101318.

Kitami K, et al. (2022) Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-??1/thrombospondin-1 axis. Matrix biology : journal of the International Society for Matrix Biology, 109, 70.

Braal CL, et al. (2021) Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 81(3), 317.

Stalin J, et al. (2020) Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors. International journal of cancer, 147(6), 1666.

Jung M, et al. (2020) ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. International journal of cancer, 147(8), 2225.